Reaction
Xeroderma reporting signals
As of the last recalculation, Xeroderma appears in 267 FAERS reports alongside 9 co-occurring drug terms. The strongest observed disproportionality signal is PANITUMUMAB (PRR 254.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Panitumumab | 43 | 254.9 | 255.6 |
| Gefitinib | 6 | 53.0 | 53.0 |
| Erlotinib | 6 | 49.4 | 49.4 |
| Erlotinib Hydrochloride | 7 | 44.8 | 44.8 |
| Trifluridine And Tipiracil | 6 | 44.6 | 44.6 |
| Oxaliplatin | 32 | 38.1 | 38.1 |
| Pemetrexed | 10 | 37.7 | 37.7 |
| Fluorouracil Cream, 0.5% | 32 | 37.0 | 37.0 |
| Fentanyl Citrate | 7 | 31.3 | 31.3 |